23 December 2009

Original: English


Meeting of the expert group on data collection

Vienna, 12-15 January 2010 Item 3 of the provisional agenda* Content and structure of a revised, simple and efficient reporting system

Draft annual report questionnaire: part III

V.09-89422 (E)





^{*} UNODC/CND/EG.1/2010/1.

Part III: Extent, patterns and trends in drug use

Report of the Government of:
Reporting Year:
Completed on (date):
Please return completed questionnaire to: arq@unodc.org
The completed ARQ is due on: [date]
For technical support, contact:

	Phone	Fax	Email
UNODC Vienna	1800 123 456	1800 654 321	arqhelp@unodc.org
Regional offices:			
[list]			

NOTE

This is a printable version of the draft revised Annual Reports Questionnaire (ARQ). The revised ARQ is in the form of an Excel spreadsheet and is designed to be completed electronically. In this printable version, definitions of key terms used in the ARQ are presented on page 3; in the electronic version these definitions (and additional instructions) are repeated throughout the questionnaire, using the 'Comments' function in Excel. The Excel spreadsheet also uses 'drop-down lists' for some questions, allowing the respondent to simply select from a list the answer that is most appropriate for their country.

Instructions

The Annual Reports Questionnaire (ARQ) consists of four parts:

Part I: Legislation
Part II: Programmes

Part III: Extent, patterns and trends of drug use

Part IV: Illicit supply of drugs This is Part III of the ARQ

Respondents are asked to **complete all questions**. Where no data are available, this should be indicated by inserting a line -- or writing 'don't know' in the appropriate cell. All questions refer to the Reporting Year, unless indicated otherwise.

Contributors

All persons who contribute to the completion of this ARQ are asked to provide their name, position and contact details, and indicate which questions they contributed to, in the Contributors section. This allows the UNODC to contact you, if further information or clarification is required.

Metadata

Contributors may refer to multiple sources in completing the ARQ. These sources may include published and unpublished reports, and/or routinely collected data from treatment, law enforcement or other agencies. All sources referred to during completion of the ARQ should be listed in the Metadata section, at the end of each Section in this questionnaire. This information helps the UNODC to interpret the information you provide.

About the questions

Part III of the ARQ asks for information at two levels, which recognises that not all countries have detailed data on all of the topics covered in the ARQ.

1. Summary expert opinions

These questions ask for broad, 'qualitative' information. All questions refer to the past calendar year, being the reporting period. If you have no data based on surveys, registers or formal estimation methods, the questions can be answered on the basis of the opinions of informed experts. These experts should be identified in the Contributors section.

2. Quantitative estimates

These questions ask for quantitative estimates. The ARQ includes standardised response categories, however should your data not conform to these categories they can still be included. Please simply indicate the categories used (for example age range, drug category) in the space provided. Estimates should be provided for the reporting year. Where this is not possible please include the most appropriate recent figures available. You should always specify the year of the estimate. If you do not have a national estimate you can specify an estimate for a part of the country or for a sub-population. If you have more than one such partial estimate, you should take the estimate that in your opinion is the best alternative for a recent national estimate. In such case you should also specify the geographical or population coverage of the estimate as simply but explicitly as possible, as well as the size of the reference population.

Several questions relate to drug classes or drug types. Whenever applicable, it is important that the information requested is reported for individual drugs. Although we have taken care to include all major drugs, the pre-coded lists might not fully suit the interests of your country. We therefore provide in each list the opportunity to add other drug classes or drug types. You may also use these open categories to insert alternative aggregate groups of drugs. For example: some questions list 'heroin' and 'other illicit opioids'; if you only have information on opioids without specification of types, you should specify 'any opioids' as 'other drugs'.

Definitions

Definitions of some key terms used in the ARQ follow.

Diverted prescription	prescription drugs deflected from medical sources to the illegal market
drugs	
Drug class	a category of drugs, such as illicit opioids or illicit amphetamine type stimulants. A drug class
	includes two or more specific drug types
Drug diversion	the deflection of prescription drugs from medical sources to the illegal market
Drug-related AIDS death	deaths among drug users where AIDS has been assessed as the direct underlying cause of
	death and drug injecting has been identified as the mode of transmission of HIV
Drug-related morbidity	diseases and other health problems associated with the use of illicit drugs
Drug-related mortality	deaths where illicit drug use is a direct or indirect contributing factor
Drug treatment	the process of intervention directed towards individual active drug users offered by providers
	of health, social or community services, aiming at ending or reducing the use of drugs or the
	negative consequences of drug use
Drug type	specific types of drugs within a drug class. For example, marijuana (herb) and hashish (resin)
	are drug types in the cannabis drug class
Fatal drug overdose	case of death where an overdose or intoxication with illicit drugs has been assessed as the
	direct underlying cause of death
Homeless (person)	person without stable or consistent accommodation
Illicit drug	any drug listed in the schedules to the international drug control conventions whose origin
	(that is, production, cultivation, sale or acquisition) was illicit or illegal
Incidence	the frequency with which an event (e.g., fatal drug overdose) occurs within a specified
	population (e.g., injecting drug users) within a specific period of time (e.g., one year)
Injecting drug user (IDU)	person who uses drugs exclusively or primarily by injecting route of administration
Non-prescribed/non-	use of diverted prescription drugs OR use of one's own prescription drugs in a manner other
therapeutic use of	than as prescribed by a medical practitioner
prescription drugs	
Prescription drug	any controlled substance that may be prescribed by a medical practitioner, whether used as prescribed or not
Prevalence	the proportion of individuals in a specified population with a given condition (e.g., HIV) or
	engaging in a particular behaviour (e.g., injecting drug use)
Prisoner	person held against their will by the State, as punishment for the commission of a crime
Problem drug user	drug user who is considered particularly problematic, chronic or in need of help/treatment
Reference population	the entire population to which an estimate applies
Sex worker	person engaging in sexual acts for the purposes of financial or other material gain
Sharing	sharing of needles or syringes means two or more people using the same needle or syringe to
	inject drugs, regardless of whether the equipment has been cleaned or disinfected

Drug Classes and Types

Listed below are the drug classes and drug types included in the ARQ. In some cases, examples of particular drug types are provided, but these examples are NOT EXHAUSTIVE.

DRUG CLASS	DRUG TYPES
Any illicit drug	
Cannabis	Cannabis herb (marijuana)
	Cannabis resin (hashish)
Illicit opioids	Heroin
	Opium
	Other illicit opioids (e.g., homebake)
Cocaine	Cocaine powder (salt)
	Crack cocaine and cocaine base
	Other cocaine types
Illicitly manufactured	Amphetamine
amphetamine type	Methamphetamine
stimulants (ATS)	Ecstasy type (e.g., MDMA, MDA, MDE/MDEA)
	Other illicit ATS (e.g., captagon, methcathinone, 4-MTA, 2C-B, MDBD)
Non-prescribed/non-	Prescription opioids (e.g., morphine, methadone, buprenorphine, suboxone, oxycodone,
therapeutic use of	hydrocodone, fentanyl, codeine, pethidine, dextropropoxyphene, hydromorphone)
prescription drugs†	Prescription stimulants (e.g., fenetylline, methylphenidate, phenmetrazine, amfepramone, pemoline, phentermine)
	Benzodiazepines (e.g., diazepam, alprazolam, temazepam, clonazepam)
	Other sedative hypnotics, including barbiturates (e.g., meprobamate, zolpidem, methaqualone,
	phenobarbital)
	Other diverted prescription drugs (e.g., tramadol, ketamine)
Hallucinogens	Lysergic acid diethylamide (LSD)
	Other hallucinogens (e.g., phencyclidine (PCP), mushrooms, tryptamines)
Solvents and inhalants	
Other illicit drugs‡	For example, gamma hydroxybutyrate (GHB), khat, piperazines (e.g., BZP)

[†] Non-prescribed/non-therapeutic use refers to use of diverted prescription drugs OR use of one's own prescription drugs in a manner other than as prescribed by a medical practitioner.

[‡] Drugs under national but not international control.

Contributors

INSTRUCTIONS: Provide details of all persons who contributed to completion of this ARQ. Each person should indicate which questions they have contributed to.

	Name	Position	Agency	Phone	Fax	Email	Questions contributed to
Example	Mr John Smith	Chief Statistician	Office of Drug Control	+44 221 6573	+44 221 6001	j.smith@odc.gov	Q6-9, 10-13
Contributor #1							
Contributor #2							
Contributor #3							
Contributor #4							
Contributor #5							

Prevalence of Drug Use: General Population

		Q1		Q2	Q3
		s drug beer ountry in t year?		Rank these drug classes in order of prevalence of use in the past year	WITHIN each drug class, rank drug types in order of prevalence of use in the past year
	No	Yes	Don't know		
Cannabis Marijuana (herb) Hashish (resin)					
Heroin Opium Other illicit opioid (specify)	_ _ _	_ _ _			
Cocaine Powder (salt) Crack and base Other cocaine type (specify)	_ _ _				
Illicitly manufactured amphetamine type stimulants (ATS) Amphetamine Methamphetamine Ecstasy type Other illicit ATS (specify)	0		_ _ _		
Non-prescribed/non-therapeutic use of prescription drugs Prescription opioids Prescription stimulants Benzodiazepines Other sedative hypnotics Other misused prescription drugs (specify)	0	0	_ _ _ _		
Hallucinogens LSD Other hallucinogens (specify)					
Solvents and inhalants					
Other illicit drugs (specify)					

					24) 5		
				valence hanged	in the					hanged	of use in the p	ast vea	
		Large increase	Some increase	No great change	Some decrease	Large decrease	Don't know	Large	Some increase	No great change	Some	Large decrease	Don't know
Cannabis Marijuana (herb) Hashish (resin)													
Illicit opioids Heroin Opium Other illicit opioid (specify)													
Cocaine Powder (salt) Crack and base Other cocaine type (specify)													
Illicitly manufactured amphetamine type stimulants (ATS) Amphetamine Methamphetamine Ecstasy type Other illicit ATS (specify)	e												
Non-prescribed/non-therapeutic use prescription drugs Prescription opioids Prescription stimulants Benzodiazepines Other sedative hypnotics Other misused prescription drugs (specify)	e of												
Hallucinogens LSD Other hallucinogens (specify)													
Solvents and inhalants													
Other illicit drugs (specify)													
METADATA What sources of information (publish	ed and	unpubli	shed) w	ere refe	rred to i	n answe	ering these	questio	ns?				

Prevalence/Number of Drug Users: General Population

Q6 Do you have an estimate of the preval □ No (go to Q10) □ Yes, for the whole population □ Yes, for part of the population	ence or nun	iber of drug u	sers amon	g the gener	al populati	on?		
Q7 For which year does the estimate appl	y?							
Which part of the country or the population	on is covere	d by the estim	ate?					
What is the estimated size of the reference	population	for which the	estimate a	applies?				
What is the source of the data on which you General population survey School survey Indirect estimate Register of drug users Other (specify)						
	XXII	Q8	EETH (E	1	****	Q9		C
	of u population	ne estimated LI se per 100 amo n? Specify sepa female	ong the gen arately for es.	eral	100 amo REPORT	he estimated p ng the general ING YEAR? S males and f	population pecify sepa females.	IN THE
		age range: 15- e used:	-		Age range Preferred Timeframe		months	_
	Number of users	% of population	% of males	% of females	Number of users	% of population	% of males	% of females
Any illicit drug Cannabis Marijuana (herb) Hashish (resin) Illicit opioids Heroin Opium Other illicit opioid (specify) Cocaine Powder (salt) Crack and base Other cocaine type (specify) Illicitly manufactured amphetamine type stimulants (ATS) * Amphetamine Methamphetamine Ecstasy type								
Other illicit ATS (specify) Non-prescribed/non-therapeutic use of prescription drugs Prescription opioids Prescription stimulants Benzodiazepines								
Other sedative hypnotics Other misused prescription drugs (specify)								

UNODC/CND/EG.1/2010/5

Hallucinogens				
LSD				
Other hallucinogens (specify)				
Solvents and inhalants				
Other illicit drugs (specify)				

do the figures reported for use of finert ATS include non-prescribed/non-therapeutic use of prescription stimulants? Tes / No (circle one)
METADATA: What sources of information (published and unpublished) were referred to in answering these questions?

^{*} do the figures reported for use of illicit ATS include non-prescribed/non-therapeutic use of prescription stimulants? Yes / No (circle one)

Prevalence/Number of Drug Users: Youth Population

Q10 Do	No (go to Q15) Yes, for the whole population Yes, for part of the population	llence or nu	mber of drug	users amo	ng the you	th populati	on?			
	Q11 For which year does the est	imate apply	?							
	Which part of the country or sub	-population	is covered by	the estim	ate?					
	What is the estimated size of the	reference po	pulation for v	which the	estimate ap	plies?				
	What is the source of the data on	which your	estimate is ba	ased?						
_ _ _ _	General population survey School survey Indirect estimate Register of drug users Other (specify)									
			Q12				Q13			
		of use po Specify	ne estimated LI er 100 among Y separately for i	YOUNG PI	EOPLE?	100 a REPORT	he estimated pr mong YOUNG ING YEAR? Sp males and f	PEOPLE : pecify sepa emales.	in the	
			age range: 15- used:		_	Preferred age range: 15-16 years Age range used: Preferred timeframe: 12 months Timeframe used:				
		Number of users	% of population	% of males	% of females	Number of users	% of population	% of males	% of females	
Any illic			population			or users	population			
Cannabi Mariju	is ana (herb)									
3	sh (resin)									
Illicit op										
Heroin Opium										
	illicit opioid (specify)									
Cocaine										
	er (salt)									
	and base									
Other	cocaine type (specify)									
stimular	manufactured amphetamine type nts (ATS) *									
	etamine mphetamine									
Ecstas										
Other	illicit ATS (specify)									
Non-nre	escribed/non-therapeutic use of									
prescrip	tion drugs									
	iption opioids									
	iption stimulants diazepines									
Other	sedative hypnotics									
Other (specify)	misused prescription drugs									

UNODC/CND/EG.1/2010/5

Hallucinogens LSD				
Other hallucinogens (specify)				
Solvents and inhalants				
Other illicit drugs (specify)				

METADATA: What sources of information (published and unpublished) were referred to in answering these questions?

Injecting Drug use

		Q14				Q1	5			Q16
	practi amor in th	ig drug ie past j	jecting users year?			as been over t				Has there been sharing of needles or syringes among drug injectors in the past year?
	No	Yes	Don't know	Large increa	Some	No great	Some decrea	Large decrea	Don't know	□No □Yes □Don't know
Any illicit drug										Q17
Heroin Opium Other illicit opioid (specify)										What has been the trend in the past year in sharing needles or syringes among injecting drug users?
Cocaine Powder (salt) Crack and base Other cocaine type (specify)										☐ Some increase ☐ No great change ☐ Some decrease ☐ Large decrease ☐ Don't know
Illicitly manufactured amphetamine type stimulants (ATS) Amphetamine Methamphetamine Ecstasy type Other illicit ATS (specify)				0 0000						
Non-prescribed/non-therapeutic use of prescription drugs Prescription opioids Prescription stimulants Benzodiazepines Other sedative hypnotics Other misused prescription drugs (specify)				0 00000						
Hallucinogens LSD Other hallucinogens (specify)										
Solvents and inhalants										
Other illicit drugs (specify)										
METADATA What sources of information (published	and un	publish	ed) were	referre	d to in	answer	ring the	ese que	stions	?

Injecting Drug Users

Q19 For which year does the estimate a	pply?		
Which part of the country or sub-group	of drug users is covered by th	e estimate?	
What is the estimated size of the reference	ce population for which the es	timate applies?	
	Q20	Q21	Q22
	What is the estimated PERCENTAGE of	What is the estimated total NUMBER OF	What is the estimated PERCENTAGE of active
	users of each drug that	INJECTORS of each	injecting drug users who
	INJECT that drug?	drug?	shared needles or syringes
		-	the LAST TIME they
			injected?
			Preferred timeframe: last time injected
			Timeframe used:
	% of users	Number of injectors	% of IDU sharing
Any illicit drug			
Illicit opioids			
Heroin			
Opium Other illicit opioid (specify)		<u> </u>	
Other fillest opioid (specify)			
Cocaine			
Illicit ATS *			
Amphetamine			
Methamphetamine			
Ecstasy type			
Other illicit ATS (specify)			
Non-prescribed/non-therapeutic use of			
prescription drugs			
Prescription opioids			
Prescription stimulants			
Benzodiazepines			
Other sedative hypnotics Other misused prescription drugs			
(specify)			
specify			
Hallucinogens			
Solvents and inhalants			
Other illicit drugs (specify)	-		
do the figures reported for use of illicit A	TS include non-prescribed/non-	theraneutic use of prescripti	ion stimulants? Yes / No (circle
do the figures reported for use of filler A	13 merude non-preserioed/non-	-therapeutic use of prescripti	ion stimulants: 1637 No (effect
METADATA			

Problem Drug Users

Q23 Do you have an estimate of the number of problem drug users in your country? □ No (go to Q29) □ Yes, for the whole country □ Yes, for part of country or sub-population
Q24 For which year does the estimate apply?
Which part of the country or sub-population is covered by the estimate?
What is the estimated size of the reference population for which the estimate applies?
Q25 What is the estimated number of problem drug users in your country?
Q26 What definition of 'problem drug user' applies to the estimate in Q25 and how was it calculated?
High Rick Groups

High Risk Groups

	Q27		Q28
	What is the estimated PERCENTAGE of each group that used an illicit drug IN THE REPORTING YEAR? Preferred timeframe: 12 months Timeframe used:		PRIMARY drug of concern igh risk group?
	% used any drug	Main drug of	concern (tick ONE)
Injecting drug users	100%	☐ Cannabis ☐ Illicit opioids ☐ Cocaine ☐ Illicit ATS ☐ Prescription drugs	☐ Hallucinogens ☐ Solvents & inhalants ☐ Other illicit drugs (specify)
Sex workers		☐ Cannabis ☐ Illicit opioids ☐ Cocaine ☐ Illicit ATS ☐ Prescription drugs	☐ Hallucinogens ☐ Solvents & inhalants ☐ Other illicit drugs (specify)
Prisoners		☐ Cannabis ☐ Illicit opioids ☐ Cocaine ☐ Illicit ATS ☐ Prescription drugs	☐ Hallucinogens ☐ Solvents & inhalants ☐ Other illicit drugs (specify)
Homeless people		☐ Cannabis ☐ Illicit opioids ☐ Cocaine ☐ Illicit ATS ☐ Prescription drugs	☐ Hallucinogens ☐ Solvents & inhalants ☐ Other illicit drugs (specify)
METADATA What sources of information	(published and unpublished) were referred to in answe	ering these questions?	

New Developments in Drug Use

Q29	Q31
Have any NEW DRUGS or NEW PATTERNS of drug use been observed in the past year?	Have any NEW GROUPS of drug users been observed in the past year?
□No (go to Q31) □Yes	□No (go to Q33) □Yes
Q30	Q32
Which new drugs or patterns of drug use have been observed?	Which new groups of drug users have been observed, and in relation to which drugs?
Q33	
Use the space below to documents any other developments in the p	prevalence and patterns of drug use in your country over the past
year.	
METADATA What sources of information (published and unpublished) were referred	ed to in answering these questions?

Blood Borne Viruses

 $Q34 \ Has \ the \ prevalence \ of \ each \ of \ these \ infections \ among \ IDU \ changed \ in \ the \ past \ year?$

	Large	Some	No great	Some	Large	Don't
	increase	increase	change	decrease	decrease	know
Hepatitis B						
Hepatitis V						
HIV						

- □ No (go to Q39)
- Yes, for the whole population
 Yes, for subgroup or part of population

O36 For which year does the estimate apply?	e estimate apply?	
---	-------------------	--

Which part of the country or sub-group of IDU is covered by the estimate?

What is the estimated size of the reference population for which the estimate applies?

	Q37	Q38
	What is the estimated number of IDU with each infection?	What is the estimated PERCENTAGE of IDU with each infection?
	Number of IDU	% of IDU
Hepatitis B		
Hepatitis V		
HIV		

METADATA
What sources of information (published and unpublished) were referred to in answering these questions?

Drug-Related Mortality

	Q39		Q40	Q41					
	Have there been reports of drug-related deaths in the past year?		Rank these drugs in order of their importance as a primary cause of death in drug-related deaths.	What has been the trend over the past year in drug-related deaths?					
	No	Yes		Large increase	Some increase	No great change	Some decrease	Large decrease	Don't know
Any illicit drug Illicit opioids Heroin Opium Other illicit opioid (specify)									
Cocaine Powder (salt) Crack and base Other cocaine (specify)		000							
Amphetamine Methamphetamine Ecstasy type Other illicit ATS (specify)	_ _ _ _	0000							
Non-prescribed/non-therapeutic use of prescription drugs Prescription opioids Prescription stimulants Benzodiazepines Other sedative hypnotics Other misused prescription drugs (specify)		0 0000 0							
Hallucinogens Solvents and inhalants									
Other illicit drugs (specify)	_ _ _	_ _ _			_ _ _	_ _ _	_ _ _	_ _ _	
METADATA What sources of information (published and unpublished) were referred to in answering these questions?									

Drug-Related Mortality

 $Q42\ Do\ you\ have\ an\ estimate\ of\ the\ NUMBER\ of\ drug-related\ deaths\ in\ your\ country?$

□ No (go to Q47)□ Yes, for the whole population□ Yes, for subgroup or part of part	oopulation		
Q43 For which year does the estimate	te apply?		
Which part of the country or sub-pop	oulation is covered by the esti	mate?	
What is the estimated size of the refe	rence population for which th	ne estimate applies?	
	Q44	Q45	Q46
	What is the TOTAL number of drug-related deaths?	What is the estimated number of FATAL OVERDOSES only?	What is the estimated number of drug-related AIDS DEATHS?
Any illicit drug			
Illicit opioids			
Cocaine			
llicit ATS			
Non-prescribed/non-therapeutic			
ise of prescription drugs			
Hallucinogens			
Solvents and inhalants			
Other illicit drugs (specify)			
METADATA			
What sources of information (published	l and unpublished) were referre	ed to in answering these question	ons?
ų.	•		

Drug Treatment

	Q47		Q48		Q49						
	Have people received treatment for problems with these drugs in the past year?		Rank these drugs in order of their importance as the primary cause of receiving treatment.		Has there been any change in the NUMBER of people receiving treatment for these drugs?						
	No	Yes				Large	Some increase	No great change	Some decrease	Large decrease	Don't know
Any illicit drug											
Cannabis											
Illicit opioids											
Cocaine											
Illicit ATS											
Non-prescribed/non-therapeutic use of prescription drugs											
Hallucinogens											
Solvents and inhalants											
Other illicit drugs (specify)					=" •						

METADATA
What sources of information (published and unpublished) were referred to in answering these questions?

Drug Treatment

□ No (go to Q57)
 □ Yes, for entire country
 □ Yes, for part of country or some treatment facilities

	Q52	Q53	Q54	Q55	Q56	Q57	
	What is the estimated NUMBER of people receiving treatment for drug problems?	What PERCENTAG E of people in drug treatment are receiving treatment for the FIRST TIME?	What PERCENTAG E of people in drug treatment are FEMALE?	What PERCENTAG E of people in treatment are INJECTING DRUG USERS?	What is the MEAN (AVERAGE) AGE of people in drug treatment?	What is the estimated number of people who NEED TREATMEN T for drug problems?	
Any illicit drug							
Cannabis Illicit opioids							
Cocaine							
Illicit ATS *							
Non-prescribed/non-							
therapeutic use of prescription drugs							
Hallucinogens							
Solvents and inhalants							
Alcohol							
Other illicit drugs (specify)							
	Q58						
Definitions		of 'drug treatme	nt' applies to the	figures reported i	n Q52-Q56 (tick)	ONE)?	
All people receiving treatment							
People starting treatment People in treatment at census							
date	Ц	Ц	Ц	Ц	Ц		
People discharged from							
treatment Other							
(specify)							
* do the figures reported for use of illicit ATS include non-prescribed/non-therapeutic use of prescription stimulants? Yes / No (circle one)							
METADATA							
What sources of information (pu	ublished and uppub	lished) were refer	red to in answering	these questions?			
what sources of information (pr	aonsnea and unput	maneuj were referi	ica to in answering	these questions?			

Q50 Do you have an estimate of the NUMBER of people receiving drug treatment in your country?

Data Collection and Monitoring Capacity

	Q59					
	HOW OFTEN does your country collect the following data regarding drug use treatment?					
	Never	Once a year	Every 2 years	Every 3-5 years	Every 6-10 years	Less often
Registers National data collection on drug treatment Register of problem drug users Register on drug-related morbidity Register on drug-related mortality						
Surveys General population prevalence surveys School population prevalence surveys Surveys among drug users Surveys among prisoners		_ _ _	_ _ _			
Qualitative Research Rapid situation assessments						
Other data collections (specify)						
Q60 What measures (if any) have been taken to It your country? What are the main barriers to	MPROVE DA	ATA COLLECTION	ON SYSTEMS	to monitor dru		
0(1 p					•	
Q61 Does your country have a DEDICATED ☐ No national body exists ☐ Yes, a national body exists Q62 Does your country bays a DEDICATED						
Q62 Does your country have a DEDICATED ☐ No dedicated budget ☐ Yes, dedicated budget	, BUDGET U	о иприсшент а па	nonai strategy	ioi ui ug uema	na reauction?	
METADATA What sources of information (published and un	published) we	re referred to in a	aswering these o	questions?		

Additional Comments

or to document any other issues that you wish to draw to the attention of the UNODC. If your comment relates to a specific question in the ARQ, please refer to the corresponding question number.

Use the space below to add notes, comments or clarification of any of the information contained in this questionnaire,